NBIX250117C145000
- 0.04
- -0.15-78.95%
Neurocrine Biosciences Newsroom
Oppenheimer Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $192
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating
Neurocrine Is Maintained at Buy by UBS
Neurocrine Biosciences Analyst Ratings
UBS Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $162
Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $160
RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Raises Target Price to $159
Neurocrine Is Maintained at Overweight by Barclays
Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $160
Wedbush Raises Price Target on Neurocrine Biosciences to $154 From $148, Keeps Outperform Rating
Barclays Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165
Needham Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating
TD Cowen Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165
BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $182
TD Cowen Reaffirms Their Buy Rating on Neurocrine (NBIX)
Neurocrine Biosciences Analyst Ratings
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $185
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $148 to $190
Wedbush Reaffirms Their Buy Rating on Neurocrine (NBIX)
Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $148 Price Target